Travere Therapeutics (TVTX) Misses Q2 EPS by 2c

Travere Therapeutics (NASDAQ: TVTX) reported Q2 EPS of ($0.10), $0.02 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $169.58 million versus the consensus estimate of $160.66 million.

For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.

You May Also Be Interested In

• Texas Instruments (TXN) Reiterated at Neutral by Cantor Fitzgerald on Upside to Earnings Power
• Academy Sports surges on earnings beat and raised guidance
• RH (RH) call put ratio 1 call to 1.5 puts into quarter results